Research output per year
Research output per year
Fingerprint
Dive into the research topics where Amy Dezern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years
Webster, J. A., Reed, M., Tsai, H. L., Ambinder, A., Jain, T., Dezern, A. E., Levis, M. J., Showel, M. M., Prince, G. T., Hourigan, C. S., Gladstone, D. E., Bolanos-Meade, J., Gondek, L. P., Ghiaur, G., Dalton, W. B., Paul, S., Fuchs, E. J., Gocke, C. B., Ali, S. A., Huff, C. A., & 10 others, Mar 2023, In: Transplantation and Cellular Therapy. 29, 3, p. 182.e1-182.e8Research output: Contribution to journal › Article › peer-review
-
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source
Sterling, C. H., Hughes, M. S., Tsai, H. L., Yarkony, K., Fuchs, E. J., Swinnen, L. J., Paul, S., Bolaños-Meade, J., Luznik, L., Imus, P. H., Ali, S. A., Jain, T., Ambinder, A., DeZern, A., Huff, C. A., Gocke, C. B., Varadhan, R., Wagner-Johnston, N., Jones, R. J. & Ambinder, R. F., Apr 2023, In: Transplantation and Cellular Therapy. 29, 4, p. 267.e1-267.e5Research output: Contribution to journal › Article › peer-review
Open Access -
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
DeZern, A. E., Zahurak, M., Symons, H. J., Cooke, K. R., Huff, C. A., Jain, T., Swinnen, L. J., Imus, P. H., Wagner-Johnston, N. D., Ambinder, R. F., Levis, M., Luznik, L., Bolaños-Meade, J., Fuchs, E. J., Jones, R. J. & Brodsky, R. A., Jun 22 2023, In: Blood. 141, 25, p. 3031-3038 8 p.Research output: Contribution to journal › Article › peer-review
-
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl, M., Abdel-Wahab, O., Wei, A. H., Savona, M. R., Xu, M. L., Xie, Z., Taylor, J., Starczynowski, D., Sanz, G. F., Sallman, D. A., Santini, V., Roboz, G. J., Patnaik, M. M., Padron, E., Odenike, O., Nazha, A., Nimer, S. D., Majeti, R., Little, R. F., Gore, S., & 30 others, Jun 1 2023, In: Blood Advances. 7, 12, p. 2709-2714 6 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
Karantanos, T., Teodorescu, P., Arvanitis, M., Perkins, B., Jain, T., DeZern, A. E., Dalton, W. B., Christodoulou, I., Paun, B. C., Varadhan, R., Esteb, C., Rajkhowa, T., Bonifant, C., Gondek, L. P., Levis, M. J., Yegnasubramanian, S., Ghiaur, G. & Jones, R., Jul 2023, In: Haematologica. 108, 7, p. 1886-1899 14 p.Research output: Contribution to journal › Article › peer-review
Open Access